{
  "primary": "APP",
  "interaction_type": "indirect",
  "upstream_interactor": null,
  "mediator_chain": [],
  "depth": 2,
  "support_summary": "Protein-protein interaction network analysis identified Amyloid Precursor Protein (APP) as a key hub related to ATXN3 function, suggesting an indirect link.",
  "functions": [
    {
      "function": "Convergent Proteolytic Processing in Neurodegeneration",
      "arrow": "regulates",
      "cellular_process": "In the neurodegenerative environment of Spinocerebellar Ataxia Type 3 (SCA3), cellular stress pathways are activated, leading to the upregulation and activation of proteases like caspases and calpains. Both mutant ATXN3 and the Amyloid Precursor Protein (APP) are known substrates for these proteases. Their cleavage generates fragments that are implicated in neurotoxicity.",
      "effect_description": "The pathogenic cascade initiated by mutant ATXN3 creates a cellular state of heightened proteolytic stress. This environment promotes the cleavage of both mutant ATXN3, producing toxic fragments that drive SCA3 pathology, and APP, which can lead to the generation of amyloid-β (Aβ) peptides. This suggests a pathological convergence where the consequences of mutant ATXN3 expression can indirectly influence APP processing by activating shared enzymatic pathways.",
      "biological_consequence": [
        "Expression of mutant ATXN3 induces cellular proteotoxic stress → Stress pathways lead to the activation of executioner proteases (e.g., caspases, calpains) → Activated proteases cleave mutant ATXN3, generating toxic polyQ-containing fragments → Simultaneously, these proteases cleave APP at specific sites → Cleavage of APP can initiate amyloidogenic processing, leading to the production of Aβ peptides → The accumulation of toxic fragments from both proteins contributes to shared neurodegenerative mechanisms."
      ],
      "specific_effects": [
        "Both mutant ATXN3 and APP are substrates for cleavage by calpains and caspases. [1, 4, 5, 11]",
        "Cleavage of mutant ATXN3 by calpains and caspases is a key event in SCA3 pathogenesis, leading to toxic fragment generation. [1, 4]",
        "Caspase-mediated cleavage of APP is associated with the production of cytotoxic fragments and synapse loss in Alzheimer's disease models. [11]",
        "Levels of amyloid-β protein 42 (Aβ42), a product of APP processing, are altered in patients with SCA3, suggesting a link in their pathophysiological pathways. [2]"
      ],
      "evidence": [
        {
          "paper_title": "A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3",
          "journal": "Brain",
          "year": 2017,
          "relevant_quote": "Ataxin-3 (ATXN3), the disease protein in MJD, was shown to be a substrate for mainly two families of proteases: caspases and calpains.",
          "pmid": "28334907"
        },
        {
          "paper_title": "Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid β-Protein-Induced Synapse Loss in Alzheimer's Disease",
          "journal": "Cell Reports",
          "year": 2020,
          "relevant_quote": "We hypothesize that one mechanism of Aβ-induced synaptic injury is related to the cleavage of amyloid β precursor protein (APP) at position D664 by caspases that release the putatively cytotoxic C31 peptide.",
          "pmid": "32610140"
        },
        {
          "paper_title": "Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment",
          "journal": "International Journal of Molecular Sciences",
          "year": 2024,
          "relevant_quote": "Moreover, in patients with SCA3, β-amyloid protein at amino acid 42 (Aβ42) is different from other neurological disorders, indicating that this may be useful for differentiating between SCA3 and cognitive and movement disorders. Perhaps they share common pathophysiological pathways that could be included in clinical trials.",
          "pmid": "39125644"
        }
      ],
      "pathway": {
        "name": "Amyloid Fibril Formation",
        "canonical_name": "Amyloid Fibril Formation",
        "ontology_id": null,
        "ontology_source": null,
        "confidence": 0.8
      },
      "pmids": [
        "28334907",
        "32610140",
        "39125644"
      ],
      "interaction_effect": "regulates",
      "interaction_direction": "main_to_primary",
      "function_effect": "regulation",
      "arrow_context": {
        "direct_from": null,
        "direct_arrow": "regulates",
        "net_from": "ATXN3",
        "net_arrow": "regulates",
        "mediator_chain": [],
        "is_indirect": true
      },
      "net_arrow": "regulates",
      "direct_arrow": "regulates",
      "net_effect": "regulation",
      "direct_effect": "regulation"
    }
  ],
  "arrow": "regulates",
  "direction": "main_to_primary",
  "intent": "regulation",
  "arrows": {
    "main_to_primary": [
      "activates"
    ]
  },
  "_chain_inferred": true,
  "is_valid": true,
  "mechanism_correction": "The interaction is not a direct activation but an indirect consequence of shared pathological pathways. Mutant ATXN3 does not directly regulate APP processing; rather, the cellular stress induced by mutant ATXN3 leads to the activation of proteases, such as caspases and calpains, which are known to cleave both proteins.",
  "mechanism": "In the neurodegenerative environment of Spinocerebellar Ataxia Type 3 (SCA3), cellular stress pathways are activated, leading to the upregulation and activation of proteases like caspases and calpains. Both mutant ATXN3 and the Amyloid Precursor Protein (APP) are known substrates for these proteases. Their cleavage generates fragments that are implicated in neurotoxicity.",
  "effect": "The pathogenic cascade initiated by mutant ATXN3 creates a cellular state of heightened proteolytic stress. This environment promotes the cleavage of both mutant ATXN3, producing toxic fragments that drive SCA3 pathology, and APP, which can lead to the generation of amyloid-β (Aβ) peptides. This suggests a pathological convergence where the consequences of mutant ATXN3 expression can indirectly influence APP processing by activating shared enzymatic pathways.",
  "summary": "ATXN3 interacts with APP to modulate convergent proteolytic processing in neurodegeneration, ultimately affecting the accumulation of toxic fragments from both proteins contributes to shared neurodegenerative mechanisms.",
  "evidence": [
    {
      "paper_title": "A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3",
      "journal": "Brain",
      "year": 2017,
      "relevant_quote": "Ataxin-3 (ATXN3), the disease protein in MJD, was shown to be a substrate for mainly two families of proteases: caspases and calpains."
    },
    {
      "paper_title": "Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid β-Protein-Induced Synapse Loss in Alzheimer's Disease",
      "journal": "Cell Reports",
      "year": 2020,
      "relevant_quote": "We hypothesize that one mechanism of Aβ-induced synaptic injury is related to the cleavage of amyloid β precursor protein (APP) at position D664 by caspases that release the putatively cytotoxic C31 peptide."
    },
    {
      "paper_title": "Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment",
      "journal": "International Journal of Molecular Sciences",
      "year": 2024,
      "relevant_quote": "Moreover, in patients with SCA3, β-amyloid protein at amino acid 42 (Aβ42) is different from other neurological disorders, indicating that this may be useful for differentiating between SCA3 and cognitive and movement disorders. Perhaps they share common pathophysiological pathways that could be included in clinical trials."
    }
  ],
  "pathways": [
    {
      "name": "Amyloid Fibril Formation",
      "canonical_name": "Amyloid Fibril Formation",
      "ontology_id": null,
      "ontology_source": null,
      "confidence": 0.8
    }
  ],
  "interaction_effect": "regulation",
  "_validation_metadata": {
    "validated": true,
    "validator": "arrow_effect_validator",
    "corrections_applied": 2
  },
  "_arrow_validated": true,
  "arrow_notation": "ATXN3 --regulates--> APP:",
  "protein_a": "ATXN3",
  "protein_b": "APP",
  "discovered_in_query": "ATXN3",
  "first_discovered": "2025-11-30T15:37:50.082572Z",
  "last_updated": "2025-11-30T15:37:50.082572Z"
}